Atorvastatin calcium

This product is a statin blood lipid regulating drug, belonging to the HMG-CoA reductase inhibitor. It is inactive itself, and the hydrolysis product after oral absorption competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.

Atorvastatin Calcium Tablets

This drug can treat elevated total cholesterol, elevated low-density lipoprotein cholesterol, elevated apolipoprotein B and elevated triglycerides. Patients with primary hypercholesterolemia, including familial hypercholesterolemia (heterozygous type) or mixed hyperlipidemia (equivalent to type IIa and IIb of Fredrickson classification), can use this product if the effects of diet therapy and other non-drug treatments are unsatisfactory. In patients with homozygous familial hypercholesterolemia, atorvastatin calcium can be used in combination with other lipid-lowering therapies or alone (when no other treatments are available) to lower total cholesterol and low-density lipoprotein cholesterol. It is mainly suitable for the treatment of hypercholesterolemia and mixed hyperlipidemia; prevention and treatment of coronary heart disease and cerebral stroke.

Oral administration, once a day, 1 tablet each time. Patients should follow a standard low-cholesterol diet before and during treatment with atorvastatin calcium. The recommended starting dose is 10 mg/day, with a dose range of 10-60 mg/day. Monitor blood lipid levels within 2-4 weeks of use, and adjust the dose accordingly based on the treatment goals and efficacy response.

(1) The most common adverse reaction of this product is gastrointestinal discomfort, and others include headache, rash, dizziness, blurred vision and taste disturbance. (2) It may occasionally cause a reversible increase in blood aminotransferase. Therefore, liver function needs to be monitored. (3) Rare adverse reactions include impotence and insomnia. (4) Rare adverse reactions include myositis, myalgia, and rhabdomyolysis, which are manifested as muscle pain, fatigue, fever, and are accompanied by increased blood creatine phosphokinase and myoglobinuria. Rhabdomyolysis can lead to renal failure, but it is rare. The combination of this product with immunosuppressants, folic acid derivatives, niacin, gemfibrozil, erythromycin, etc. may increase the risk of myopathy. (5) There have been reports of hepatitis, pancreatitis and allergic reactions such as angioedema.

(1) It is contraindicated in patients who are allergic to atorvastatin. It should be used with caution in patients who are allergic to other HMG-CoA reductase inhibitors. (2) It is contraindicated in patients with active liver disease or unexplained persistent elevation of blood aminotransferase.

(1) The combined use of this product with oral anticoagulants can prolong the prothrombin time and increase the risk of bleeding. (2) The combined use of this product with immunosuppressants such as cyclosporine, erythromycin, gemfibrozil, niacin, etc. can increase the risk of myolysis and acute renal failure. (3) Colestipol and cholestyramine can reduce the bioavailability of this product, so this product should be taken 4 hours after taking the former.

Keep away from light and store in sealed container.

API